Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
National Institutes of Health · Opportunity number PAR-25-327
Details summarized from the official notice as of Oct 15, 2026. Always confirm eligibility, deadlines and requirements in the official notice before applying.
Independent platform. Not affiliated with or endorsed by any government agency. Data from public federal sources.
Key facts
| Opportunity number | PAR-25-327 |
|---|---|
| Agency | National Institutes of Health Department of Health and Human Services |
| Assistance listing (ALN, formerly CFDA) | 93.853 |
| Posted | Dec 18, 2024 |
| Deadline | Oct 8, 2027 |
| Cost sharing or matching required | No |
| Funding type | Cooperative agreement |
| Category | Health |
| Last updated here | Oct 15, 2026 |
Summary from the notice
Who can apply
The official notice lists these applicant types as eligible:
- City or township governments
- For-profit organizations other than small businesses
- Small businesses
- Others named in the notice (see the eligibility text)
- Private colleges and universities
- Independent school districts
- County governments
- Special district governments
- Public and Indian housing authorities
- Nonprofits without 501(c)(3) status (other than colleges)
- State governments
- Nonprofits with 501(c)(3) status (other than colleges)
- Public and state colleges and universities
- Federally recognized tribal governments
- Other Native American tribal organizations
Who should take a closer look
- Small businesses
- Nonprofits
- Colleges and universities
- State governments
- Local governments
- Tribal governments and organizations
- Larger for-profit companies
Not listed as eligible
- Individuals
Unless the eligibility text in the notice names you, this opportunity is probably not for you.
Eligibility details from the notice
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Registrations you will likely need
Most applications submitted through Grants.gov need the following. Registration can take several weeks, so start early. The notice lists the exact requirements.
- SAM.gov registration for your organization, which also gives you a Unique Entity ID (UEI). Registration is free.
- A Login.gov account, which Grants.gov uses for sign-in.
- A Grants.gov applicant registration linked to your organization's UEI.
Similar open opportunities
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
National Institutes of Health · PAR-25-077
Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
National Institutes of Health · PAR-25-155
Community Engagement Evaluation and Data Coordination (CEED) Hub to Advance Data and Practice Transformation for Optimizing Oral Health for All (U01, Clinical Trial Not Allowed)
National Institutes of Health · RFA-DE-27-001
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · RFA-CA-27-021
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · RFA-CA-27-020